Cell and Gene Therapy Trials Surge Globally, Led by Oncology and Asia-Pacific Region
核心洞察
Global clinical trials for cell and gene therapies have expanded by 32.5% between 2019 and 2023, indicating rapid growth in the field.
CAR-T therapies (搜索) constitute a significant portion (32%) of the pipeline, primarily targeting hematological cancers (搜索), showcasing a strong focus on oncology.
The Asia-Pacific region leads in trial activity, accounting for 44% of all trials, with China being a major driver in the region's growth.
Novotech (搜索)'s latest whitepaper reveals a significant surge in cell and gene therapy clinical trials, particularly in oncology, with the Asia-Pacific region leading the charge. The report, which analyzes emerging trends and advancements in this rapidly evolving field, highlights the increasing importance of these therapies in treating various diseases.
Global Expansion of Clinical Trials
The whitepaper indicates that there are over 1,500 drug candidates in development across phases 0 to III. CAR-T therapies (搜索) represent a substantial 32% of the pipeline, primarily focused on hematological cancers (搜索). From 2019 to 2023, the global trial landscape experienced a 32.5% growth, with Asia-Pacific accounting for 44% of all trials.
Oncology Focus
CAR-T and CAR-NK therapies (搜索) constitute approximately 30% of all cell and gene therapy trials, demonstrating a strong emphasis on both solid and hematological malignancies. Significant attention is being directed towards gastrointestinal tract and lung cancers (搜索), as well as hematological cancers (搜索) such as diffuse large B-cell lymphoma (搜索) (DLBCL (搜索)).
Geographic Leadership
The Asia-Pacific region exhibits strong growth, driven primarily by China, which accounts for 56% of the region's cell and gene therapy trials. In North America, the U.S. dominates with 85% of the trials, while in Europe, key players include the UK, Spain, and Germany. Patient recruitment is also faster in Asia-Pacific (16.07 months) compared to the U.S. (21.15 months), indicating higher enrollment efficiency in the region.
Technological Advancements and Investment
Artificial intelligence (AI) and Contract Development and Manufacturing Organizations (CDMOs) are playing a transformative role in the cell and gene therapy landscape, enhancing manufacturing efficiency and trial scalability. Venture capital investment in cell and gene therapies peaked in 2021, with sustained funding for start-ups and growth-stage companies, reflecting strong investor confidence in the field.
Novotech (搜索)'s whitepaper underscores the substantial potential of cell and gene therapies, particularly in oncology, and highlights opportunities for increased collaboration in global clinical trials to accelerate research efforts.